Welcome to our dedicated page for Twist Bioscience Corporation news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience Corporation stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
The DNA Data Storage Alliance, created by Twist Bioscience (TWST), Illumina (ILMN), and Western Digital (WDC), has published a white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.” This document discusses DNA storage's potential to address the exponential growth of digital data, highlighting that humans generated over 400 ZB of data in 2020. The paper outlines DNA's unprecedented storage density, stability, and sustainability compared to existing technologies. The Alliance aims to develop standards for interoperability in DNA storage solutions as the technology evolves.
Twist Bioscience (Nasdaq: TWST) has commenced shipping synthetic RNA reference controls for the SARS-CoV-2 Kappa variant (B.1.617.1). The company is also developing controls for the Delta (B.1.617.2) and B.1.617.3 variants. This initiative comes as India faces a significant COVID-19 outbreak and a high number of unvaccinated individuals. CEO Emily M. Leproust highlighted the company's commitment to provide essential tools to combat the virus globally, including controls for detecting new strains. Twist aims to support health and sustainability through its sophisticated DNA synthesis platform.
Twist Bioscience Corporation (Nasdaq: TWST) has launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to enhance accuracy and efficiency in library construction for next-generation sequencing (NGS). This kit is particularly suitable for challenging applications, including liquid biopsy and somatic variant testing, and excels with samples of limited or degraded DNA, such as banked oncology samples. The launch emphasizes the importance of robust sample preparation technologies for generating high-quality sequencing data.
Twist Bioscience Corporation (NASDAQ: TWST) announced participation in two upcoming virtual investor conferences. CEO Emily Leproust and CFO Jim Thorburn will present at the Jefferies Virtual Healthcare Conference on June 1 at 11:30 AM ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 3:50 PM ET. Both presentations will be webcast live and available for replay for 30 days. Twist Bioscience is known for its innovative synthetic DNA technology, providing products across various sectors including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) announces its support for the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research. This initiative aims to advance ethical standards in engineering biology, which has significantly impacted fields like medicine and agriculture. The U.S. engineering biology sector contributed 5.1% to GDP in 2016. Twist emphasizes its commitment to biosecurity and ethical practices while encouraging collaboration among the scientific community to ensure responsible innovation.
Twist Bioscience (NASDAQ: TWST) reported strong financial results for Q2 FY2021, ending March 31, 2021. Total orders reached $41.7 million, up from $24.6 million year-over-year. Revenue grew to $31.2 million, compared to $19.3 million in the prior year. However, net loss for the quarter increased to $37.9 million, or $0.78 per share. The cash position stood robust at $555.7 million. The company is optimistic about growth in the second half of the fiscal year, particularly in its NGS and synthetic biology segments.
Twist Bioscience (Nasdaq: TWST) has announced a collaboration with Vivlion GmbH to develop CRISPR gRNA libraries for various applications in genome engineering and drug development. This partnership leverages Twist's high-quality synthetic DNA production capabilities and Vivlion's innovative 3Cs technology for creating uniform CRISPR libraries. The collaboration aims to enhance genomic research efficiency, enabling faster gene function analysis. The joint effort is expected to significantly impact R&D in functional genomics.
Twist Bioscience Corporation (NASDAQ: TWST) has announced plans to release its financial results for the fiscal 2021 second quarter on May 6, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results and provide a business update. The financial results will be accessible on the company's website under Investor Relations. Twist Bioscience is focused on pioneering DNA synthesis technology, catering to diverse industries including healthcare and agriculture.
Twist Bioscience Corporation (NASDAQ: TWST) has expanded its lease for the 'Factory of the Future' near Portland, Oregon, adding approximately 100,000 square feet to its existing 110,000-square-foot facility. This expansion supports the company's planned growth in synthetic DNA, including potential verticals like DNA data storage. CEO Emily M. Leproust emphasized the need for strategic space planning for future market opportunities. The financial commitment for the expansion begins in 2022, aiming to bolster Twist’s capabilities in synthetic biology and genomics.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a partnership with Pure Biologics to enhance the discovery of immuno-oncology antibody-based drugs. Through this collaboration, Twist Biopharma will provide Pure Biologics with access to synthetic antibody phage display libraries, optimized with advanced techniques including AI and big data analytics. The partnership aims to identify and optimize novel antibody candidates for therapeutic applications, with Pure Biologics committing to annual technology access fees and future milestone payments for successful outcomes.
FAQ
What is the current stock price of Twist Bioscience Corporation (TWST)?
What is the market cap of Twist Bioscience Corporation (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
